Статья

Comparison of national/regional diabetes guidelines for the management of blood glucose control in non-western countries

P. Home, J. Haddad, Z. Latif, P. Soewondo, Y. Benabbas, L. Litwak, S. Guler, J. Chen, A. Zilov,
2021

Introduction: Development of higher standards for diabetes care is a core element of coping with the global diabetes epidemic. Diabetes guidelines are part of the approach to raising standards. The epidemic is greatest in countries with recent rises in income from a low base. The objective of the current study was to investigate the availability and nature of locally produced diabetes guidelines in such countries. Methods: Searches were conducted using Medline, Google, and health ministry and diabetes association websites. Results: Guidelines were identified in 33 of 75 countries outside North America, western Europe, and Australasia. In 25 of these 33 countries, management strategies for type 1 diabetes were included. National guidelines relied heavily on pre-existing national and international guidelines, with reference to American Diabetes Association standards of medical care and/or other consensus statements by 55%, International Diabetes Federation by 36%, European Association for the Study of Diabetes by 12%, and American Association of Clinical Endocrinologists by 9%. The identified guidelines were generally evidence-based, though there was some use of secondary evidence reviews, including other guidelines, rather than original literature reviews and evidence synthesis. In type 1 diabetes guidelines, the option of different insulin regimens (mostly meal-time? basal or premix regimens) was recommended depending on patient need. Type 2 diabetes guidelines either recommended a glycosylated hemoglobin target of \7.0% (\53 mmol/mol) (70% of guidelines) or\6.5% (\47 mmol/mol) (30% of guidelines) as the ideal glycemic target. Most guidelines recommended a target fasting plasma glucose that fell within the range of 3.8-7.2 mmol/L. Most guidelines also set a 2-h post-prandial glucose target value within the range of 4.0-8.3 mmol/L. Conclusion: While only a first step in achieving a high quality of disease management, national guidelines of quality and with fair consistency of recommendations are becoming prevalent globally. A further challenge is implementation of guidelines, by integration into local care processes. © The Author(s) 2013.

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • P. Home
    Institute of Cellular Medicine, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom
  • J. Haddad
    Division of Endocrinology, Department of Internal Medicine, Prince Hamazah Hospital, Hani Rifai 34, Amman, Jordan
  • Z. Latif
    Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorder (BIRDEM), 122, Kazi Nazrul Ave, Shahbag, Dhaka, Bangladesh
  • P. Soewondo
    University Indonesia, Jl Salemba Raya no 6 Jakarta, Pusat 10430, Indonesia
  • Y. Benabbas
    Department of Medicine, University Hospital of Constantine, Cité Geric bat.9 Ain-Smara, 25140 Constantine, Algeria
  • L. Litwak
    Diabetes and Metabolism Section, Hospital Italiano de Buenos Aires, Lafinur 3050 Piso 88 Dpto. 2, (1425), Buenos Aires, Argentina
  • S. Guler
    Ankara Numune Training and Research Hospital, Sihhiye, Ankara 06100, Turkey
  • J. Chen
    Novo Nordisk, International Operations A/S, Thurgauerstrasse 36, 8050 Zurich, Switzerland
  • A. Zilov
    Department of Endocrinology, First Moscow State Medical University, 1 Pogodinskaya Street, Moscow 119435, Russian Federation
Название журнала
  • Diabetes Therapy
Том
  • 4
Выпуск
  • 1
Страницы
  • 91-102
Ключевые слова
  • 2, 4 thiazolidinedione derivative; alpha glucosidase inhibitor; dipeptidyl peptidase IV inhibitor; glucagon like peptide 1 receptor agonist; glucose; hemoglobin A1c; insulin aspart; insulin detemir; insulin glargine; insulin lispro; long acting insulin; low density lipoprotein; metformin; short acting insulin; sulfonylurea; unclassified drug; article; blood glucose monitoring; comparative study; diabetes mellitus; disease association; health care personnel; hospitalization; human; insulin dependent diabetes mellitus; non insulin dependent diabetes mellitus; postprandial state; practice guideline; priority journal
Издатель
  • Springer Healthcare
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus